Summary
Atherosclerosis is a multifactorial disease which culminates in the ruptured plaque seen at autopsy. Hypercholesterolaemia, subintimal accumulation of lipid, monocyte adhesion followed by penetration across the endothelium, the conversion of monocytes to macrophages and smooth muscle cell proliferation and migration are some of the events involved in the early stages of lesion formation. Late events include the formation of excess ground substance and collagen, and the formation of the fibrotic cap. Young lesions tend to be more fragile than “old” calcified lesions, and it is these young lesions which rupture, haemorrhage and provide anchor points for platelets.
Therapeutic interventions aimed at controlling lesion formation include those which reduce risk factors, including hypertension as well as those which interfere with the cascade of events involved in lesion formation. Agents which lower plasma cholesterol provide one approach. Another approach is to use calcium antagonists which not only lower blood pressure, but also directly interfere with some of the metabolic events involved in lesion formation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Daly MJ, Elz JS, Nayler WG (1987) Contracture and the calcium paradox in the rat heart. Circ Res 61: 560–569
Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grun G (1990) Excessive mural calcium overload a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drugs Ther 4: 1005–1014
Fuster V, Stein B, Ambrose JA, Badimon I, Badimon JJ, Chesbro JH (1990) Atherosclerotic plaque rupture and thrombis: evolving concepts. Circulation 82 (Suppl II): 11–47–11–59
Gottlieb SO, Brinker JA, Mellitis ED, Aschuff SC, Baughman KL. Traill TA, Weiss JL, Reitz BA, Weisfeldt M, Gerstenblith G (1989) Effect of nifedipine on the development of coronary bypass graft stenosis in high-risk patients: a randomized double-blind, placebo- controlled trial. Circulation 80 (Suppl 2) 11–228 (abstract)
Henry PD, Bentley KI (1981) Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 68: 1366–1369
Kramsch DM, Aspen AJ, Rozier LJ (1981) Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids.Science 213: 1511–1512
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW (1990) Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 335: 1109–1113
Loaldi A, Polese A, Montorsi P, De Cesare N, Fabbiocchi F, Ravagnani P, Guazzi M (1989) Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary artery narrowing in angina pectoris. Am J Cardiol 64: 433–439
Nayler WG (1991) Molecular mechanisms involved in the anti-atherogenic effect of the calcium antagonists. In: Nayler WG, The Second Generation of Calcium Antagonists, Springer Verlag, Berlin, pp 139–151
Nayler WG, Pangiotopoulos S (1986) Calcium antagonism. In: Kelly DT(ed) Proceedings of II Asian Pacific Adalat Symposium, ADIS Press, New Zealand, pp 3–11
Neuser D, Rosen B (1990) Calcium antagonists and the proliferation of vascular smooth muscle cells. Satellite Symposium of 13th ISH meeting Montreal “Antiatherosclerotic Potential of Calcium Antagonists” pp 9–10
Nilsson I, Sjolund M, Palmberg L, Von Euler AM, Jonzon B, Thyborg I (1985) The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 58: 109–112
Orekov AN, Tertov VU, Khashimov KA, Kudryashou SA, Smirnov VN (1986) Anti- atherosclerotic effects of verapamil in primary culture of human aortic intimal cells. J Hypertens 4 (Suppl 6): S 153–155
Ranganthan S, Jackson RL (1984) Effect of calcium channel blocking drugs on lysosomal function in human skin fibroblasts. Biochem Pharmacol 33: 2377–2382
Ross R (1981) Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1: 293–311
Ross R (1986) The pathogenesis of atherosclerosis - an update. New England J Med 314: 488–500
Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis. New England J Med 295: 369–377
Schwartz CJ, Kelley J, Nerem RM, Sprague EA (1989) Pathophysiology of the atherogenic process. Am J Cardiol 64: 236–305
Stein O, Stein Y (1987) Effect of verapamil on cholesteryl ester hydrolysis and re-esteiifica- tion in macrophages. Atherosclerosis 7: 578–584
Stein O, Halpenis G, Stein Y (1987) Long term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolaemic serum. Atherosclerosis 7: 585–592
Tonks BD (1967) The estimation of cholesterol in serum: a classification and critical review of methods. Clin Biochem 1: 12–29
Ware JA, Johnson PC, Smith M, Salzman EW (1986) Inhibition of human platelet aggrega-tion and cytoplasmic calcium response by calcium antagonists. Circ Res 59: 39–42
Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang Y-K, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ (1990) A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82: 1940–1953
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Nayler, W.G. (1994). Therapeutic approaches to the control of coronary atherosclerosis. In: Just, H., Hort, W., Zeiher, A.M. (eds) Arteriosclerosis. Steinkopff. https://doi.org/10.1007/978-3-642-85660-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-85660-0_13
Publisher Name: Steinkopff
Print ISBN: 978-3-642-85662-4
Online ISBN: 978-3-642-85660-0
eBook Packages: Springer Book Archive